Literature DB >> 21862119

Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study.

Annamaria Ferrero1, Daniela Dompè, Nicoletta Ravarino, Angela Ramella, Luca Fuso, Furio Maggiorotto, Elisa Tripodi, Paolo Zola.   

Abstract

OBJECTIVE: The role of molecular markers in ovarian cancer is still a matter of debate. Angiogenesis is a necessary condition for tumor growth. Hypoxia induces angiogenesis, and cyclooxygenase-2 (COX-2), p53 and HER2 are involved in cancer proliferation and angiogenesis regulation. The aims of this study were to evaluate the relationship between intratumoral microvessel density (IMD) and the expression of molecular markers that affect angiogenesis (COX-2, p53 and HER2) in advanced epithelial ovarian cancer (EOC), to analyze their prognostic and predictive value and their association with clinicopathological features, such as serum hemoglobin level at diagnosis (Hb).
METHODS: Immunohistochemical staining with CD34 (for IMD), COX-2, p53 and HER2 antibodies was performed in 113 patients with advanced EOC who had undergone primary surgery. Clinicopathological data were collected and statistical analyses were performed.
RESULTS: Neither IMD, COX-2 nor HER2 had any predictive or prognostic value in EOC. A relationship that approached statistical significance was found between p53 expression and a complete response to treatment (p=0.05). p53 expression and tumor grade were inversely associated (p=0.012). Hb<12g/dl had predictive value (p=0.02).
CONCLUSIONS: In our series IMD, COX-2 and HER2 had neither prognostic nor predictive value in advanced EOC. p53 and Hb may be predictive factors. The results and clinical usefulness of immunohistochemistry are controversial. Further evaluations are required to determine whether the serum levels of molecular markers correlate with the results of immunohistochemical assays and whether they offer any prognostic and/or predictive value. Targeted therapy remains the ultimate goal of these studies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862119     DOI: 10.1016/j.ygyno.2011.07.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue.

Authors:  Koen M Marien; Valerie Croons; Yannick Waumans; Ellen Sluydts; Stefanie De Schepper; Luc Andries; Wim Waelput; Erik Fransen; Peter B Vermeulen; Mark M Kockx; Guido R Y De Meyer
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

2.  COX-2 expression in ovarian cancer: an updated meta-analysis.

Authors:  Haiming Sun; Xuelong Zhang; Donglin Sun; Xueyuan Jia; Lidan Xu; Yuandong Qiao; Yan Jin
Journal:  Oncotarget       Date:  2017-10-04

3.  Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.

Authors:  Kai Wang; Chenan Guan; Junhui Yu; Xiaoxiao Jin; Ling Sun; Lingzhi Zheng; Liang Xia; Yuquan Zhang
Journal:  Oncotarget       Date:  2017-09-06

4.  Endocan-microvascular Density in Primary Ovarian Carcinoma.

Authors:  Farahlina Baba; Aidy Irman Yajid; Siti Norasikin Mohd Nafi; Siti Azrin Ab Hamid; Wan Nor Asyikeen Wan Adnan; Nur Asyilla Che Jalil
Journal:  Asian Pac J Cancer Prev       Date:  2022-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.